Brian L. Kotzin's most recent trade in Biora Therapeutics Inc was a trade of 12,500 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 5, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 12,500 | 30,746 | - | 0 | Common Stock | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2024 | 25,000 | 100,000 (0%) | 0% | 0 | Common Stock | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 12,500 | 18,246 | - | 0 | Common Stock | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 25,000 | 75,000 (0%) | 0% | 0 | Common Stock | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 03 Jan 2023 | 44 | 0 | - | - | Series X Preferred Stock | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 148,810 | 148,810 | - | - | Stock Option (Right to Buy) | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 96,154 | 143,672 | - | 0 | Common Stock | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Rigel Pharmaceuticals | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2022 | 25,000 | 50,000 (0%) | 0% | 0 | Common Stock | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 51,724 | 51,724 | - | - | Stock Option (Right to Buy) | |
| Biora Therapeutics Inc | Brian L. Kotzin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 29,183 | 47,518 | - | 0 | Common Stock |